相关实验视频

Updated: Jan 13, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

在体外分析中整合,以改善抗体-药物结合体候选人选择

Virginia Del Solar¹, Ali Saleh¹, Annarita Di Tacchio¹

¹Oncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK.

|January 10, 2026

概括

先进的分析方法和计算工具加速了抗体-药物联合体 (ADC) 的开发. 将体外稳定性测试与数据分析相结合,可以改善临床成功的候选人选择.

科学领域:

生物制药开发生物制药开发
药物发现和设计药物发现和设计
分析化学分析化学

背景情况:

抗体-药物合物 (ADC) 开发面临着合化学,链接器稳定性和分析控制方面的挑战.
早期查和ADC候选物的表征需要先进的分析方法,包括血稳定性测定和酶学研究.
将体外测定与数据分析软件相结合,对于评估结构-活性关系和识别稳定的化合物至关重要.

研究的目的:

检查综合分析和计算方法如何增强ADC候选人选择.
提供关于ADCs代谢命运和稳定性风险的见解.
为了证明早期分析研究对体内表现的预测能力.

主要方法:

使用综合分析和计算方法进行ADC候选人的评估.
进行体外血稳定性测定和酶学研究.
采用数据分析软件来可视化和评估结构-活动关系.

主要成果:

在体外稳定性概况和体内药理动力学 (PK) 数据之间证明了相关性.
展示了ADC开发早期分析研究的预测能力.
通过软件驱动的分析,实现了更快的,基于数据的决策,简化了候选人优先级.

结论:

集成的体外分析和计算工具对于有效的ADC开发至关重要.
这些综合方法支持选择具有高临床成功潜力的候选人.
促进了ADCs从发现到临床应用的加速和更有效的途径.

关键词:

在ADC的血清稳定性.抗体药物联结物抗体药物联结物计算整合计算整合酶性检测法酶性检测法

更多相关视频

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Purification and Analytics of a Monoclonal Antibody from Chinese Hamster Ovary Cells Using an Automated Microbioreactor System

Published on: May 1, 2019

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries

Published on: January 17, 2015

相关概念视频

Drug Product Performance: In Vitro–In Vivo Correlation

Drug Product Performance: In Vitro–In Vivo Correlation

In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...